Axcella Health News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.09.23	Pre-market Movers: RLMD, BROG, VSME, AXLA, NKE… (RTTNews)
23.01.23	Axcella Up 65% After Announcing Regulatory Path To Registration Of AXA1125 For Long COVID Fatigue (RTTNews)
15.12.22	Axcella Announces Series Of Organizational And Program Updates; Reduces Workforce By 85% (RTTNews)
13.10.22	Axcella Enters Into Securities Purchase Agreement - Quick Facts (RTTNews)
29.09.22	Axcella Reports Encouraging Interim Data From EMMPACT Study Of AXA1125 (RTTNews)
06.09.22	Axcella Awaits Interim Data From EMMPACT NASH Study (RTTNews)
02.08.22	Axcella Reports Positive Phase 2a Study Results Of Its Drug AXA1125 For Long COVID (RTTNews)
31.03.22	AXLA Awaits Data Readouts In Q3, ICVX On Watch, PHR Sees 27%-29% Revenue Growth (RTTNews)
15.02.22	INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT (PR Newswire)
13.10.21	Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change (PR Newswire)
27.08.20	Axcella’s Late-Breaker Data from AXA1125-003 Clinical Study Presented at the EASL Digital International Liver Congress (Businesswire)
20.08.20	Axcella Announces Upcoming Later-Breaker Presentation at The Digital International Liver Congress 2020 (Businesswire)
17.08.20	Results of Axcella’s AXA1665-001 Clinical Study Published in Clinical and Translational Gastroenterology (Businesswire)
05.08.20	Axcella Reports Positive Top-Line Data from AXA1665-002 and Second Quarter Financial Results (Businesswire)
03.08.20	Axcella to Report Second Quarter 2020 Financial Results and Hold Conference Call on August 5, 2020 (Businesswire)
17.06.20	Axcella Announces Patent Issuances Covering AXA1665 (Businesswire)
03.06.20	Axcella to Present at Goldman Sachs 41st Annual Global Healthcare Conference (Businesswire)
22.05.20	Stock Alert: Axcella Health Up 27% (RTTNews)
21.05.20	Will Data From Liver Disease, Sickle Cell Disease Trials Give Axcella A Boost? (RTTNews)
18.05.20	Axcella Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option (Businesswire)
14.05.20	Axcella Announces Pricing of Public Offering of Common Stock (Businesswire)
11.05.20	Axcella Reports First Quarter Financial Results and Provides Business Update (Businesswire)
06.05.20	Stock Alert: Axcella Health Gains 25% (RTTNews)
06.05.20	Axcella Announces Positive Top-Line Data from AXA1125-003 Clinical Study Showing Multifactorial Activity in Adult Subjects with NAFLD (Businesswire)
05.05.20	Axcella to Report Top-Line Data from AXA1125-003 in Adult Subjects with NAFLD on May 6, 2020 (Businesswire)
04.05.20	Axcella to Hold Virtual-Only 2020 Annual Meeting of Stockholders (Businesswire)
07.04.20	Axcella Receives Fourth Patent Covering EMM Compositions (Businesswire)
23.03.20	Axcella Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update (Businesswire)
05.03.20	Axcella Announces Oral Presentation at 2020 International Conference on Frailty and Sarcopenia Research (Businesswire)
26.02.20	Axcella Completes Enrollment of Subjects in AXA1665-002 Study (Businesswire)
19.02.20	Axcella to Present at the SVB Leerink 9th Annual Global Healthcare Conference (Businesswire)
09.01.20	Axcella to Present at J.P. Morgan Healthcare Conference (Businesswire)
08.01.20	Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones (Businesswire)
23.12.19	Healthcare IPOs That Disappointed Investors In 2019 (RTTNews)
08.12.19	At The ASH 2019 Annual Meeting: AXLA, CBMG, SRRA, EPZM, STOK... (RTTNews)
07.12.19	Axcella Presents Data at ASH Annual Meeting (Businesswire)
25.11.19	Axcella Strengthens Executive Team with Key Addition and Promotion (Businesswire)
20.11.19	Axcella Announces Issuance of Broad Patent Covering EMM Compositions (Businesswire)
12.11.19	Axcella Health Reports Third Quarter 2019 Financial Results and Provides Company Update (Businesswire)
08.11.19	Axcella Presents Data at The Liver Meeting™ Providing New Mechanistic Insights on Observed Multifactorial Effects of its Liver Product Candidates (Businesswire)
06.11.19	Axcella Achieves Initial Milestones with its Hematology Product Candidate AXA4010 (Businesswire)
23.10.19	Axcella Enters into Collaboration with CYTOO to Explore Impact of Dysregulated Metabolism on Muscle Physiology (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Axcella Health Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten